X4 Pharmaceuticals (XFOR) Misses Q3 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall St set for higher open as AI stocks rise, oil slides
- Streamflation drives 39% of Americans to cancel streaming in 6 months
X4 Pharmaceuticals Reports Third Quarter 2019 Financial Results and Recent Business Highlights
November 7, 2019 7:00 AM ESTReceived orphan drug designation from the European Commission for mavorixafor for treatment of WHIM Syndrome
Reported positive data from Phase 2a clinical trial of mavorixafor in combination with axitinib in advanced clear cell renal cell carcinoma patients
Hosts investment community conference call at 8:00 a.m. ET on November 7, 2019
CAMBRIDGE, Mass.--(BUSINESS... More
